Mouse Monoclonal to CD253 / TRAIL

2E5 (IgG1)

	Product No.	Form	Quantity	Stock	Price	Datasheet	Shop
	10-316-C025	azide free	0.025 mg		choose region
	10-316-C100	azide free	0.1 mg		choose region

- In stock! Ready for immediate despatch

- Manufacture on order

Background

Human CD253 / TRAIL (TNF-Related Apoptosis Inducing Ligand), also called Apo2, is a type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261 / TRAIL-R1) and DR5 (CD262 / TRAIL-R2).

Entrez Gene: 3q26

Specificity

The antibody 2E5 reacts with TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also in many other tissues.

Immunogen

Recombinant soluble fragment (aa 95-281) of human TRAIL.

Species Reactivity: Human Negative Species: Mouse Other not tested	Applications: Functional Application The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays. Flow Cytometry Recommended dilution:1-10 μg/ml Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.	Product Specific References Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T: TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 2002 Jan;16(1):67-73. [Abstract] Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC: Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005 Jun 1;65(11):4799-808. [Abstract] [Full Text]

Species Reactivity:

Human

Negative Species:

Mouse
Other not tested

Applications:

Functional Application
The antibody 2E5 has high neutralizing activity for human TRAIL in biological assays.
Flow Cytometry
Recommended dilution:1-10 μg/ml

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

*Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T: TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 2002 Jan;16(1):67-73. [Abstract]

*Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC: Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 2005 Jun 1;65(11):4799-808. [Abstract] [Full Text]

For research use only. Not for drug, diagnostic or other use.

Related Products

Mouse IgG1 Isotype Control

Example Data

Fig. 1. Induction of apoptosis

Fig. 1. Apoptosis induced in JURKAT human T cell leukemia cell line by soluble recombinant human TRAIL is completely blocked by anti-human TRAIL (2E5).
The neutralizing activity of the antibody 2E5 has been confirmed with various sources of soluble recombinant human TRAIL.
A - medium
B - recombinant TRAIL
C - recombinant TRAIL + anti-human TRAIL (2E5; 0.06 μg/ml)
D - recombinant TRAIL + anti-human TRAIL (2E5; 0.24 μg/ml)
E - recombinant TRAIL + Isotype mouse IgG1 control

PRODUCTS